Cti Biopharma Corp (NASDAQ:CTIC) Short Interest Increased By 1.94%

April 16, 2018 - By Patrick Harkless

CTI BioPharma Corp. (NASDAQ:CTIC) Corporate Logo

Cti Biopharma Corp (NASDAQ:CTIC) recorded an increase of 1.94% in shorted shares. FINRA issued shorted shares of CTIC’s total 441,900 shares. That’s 1.94% up from 433,500 shares. With Average volume 115,200, CTIC’s former position will take 4 days to recover. Float short on Cti Biopharma Corp is 1.84%.

On during the last trading session the stock decreased $0.07 or 1.80%, reaching $3.82.Currently CTI BioPharma Corp. is downtrending after 7.09% change in last April 16, 2017. CTIC has also 64,480 shares volume. CTIC underperformed by 18.64% the S&P500.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.The company has $221.49 million market cap. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union.Currently it has negative earnings. The firm is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis.

CTI BioPharma Corp. (NASDAQ:CTIC) Ratings Coverage

Total analysts of 3 have positions in CTI BioPharma (NASDAQ:CTIC) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since February 23, 2018 according to StockzIntelligence Inc CTI BioPharma has 3 analyst reports. On Monday, March 26 Needham initiated CTI BioPharma Corp. (NASDAQ:CTIC) with “Buy” rating.

CTI BioPharma Corp. (NASDAQ:CTIC) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: